binds to Hip1, Patched1 (Ptch1) and Patched2 (Ptch2) transmembrane receptors by diffusion. 9 The transmembrane receptors Ptch1 Generally, Gli1 protein acts as a transcriptional activator, and Gli3 protein acts as a transcriptional suppressor. After translation and shear, the N-terminus of Gli1 finally becomes a transcriptional activator and enters the cell nucleus where it activates the transcription of downstream genes. Hedgehog signaling pathway activation can promote tumor cell growth, migration, metastasis and in vivo tumorigenesis. 11 In hepatic stellate cells, the Hedgehog signaling pathway is activated, which promotes hepatoma cell angiogenesis and vasculogenic mimicry. 12 Previous studies have indicated that activated Hedgehog signaling has important functions in HCC occurrence and development.
The Krüppel-like factor (KLF) family comprises transcription factors with a zinc finger domain and includes 17 members.
13
Studies showed that the KLF family can regulate multiple biological processes, such as cell proliferation, differentiation and migration, among others. The KLF family has important functions in the occurrence of multiple tumor types. For example, KLF2 participates in the genesis and development of intestinal cancer and breast cancer, 14 KLF5 plays an important role in the progression of esophageal cancer and lung cancer, 15, 16 and KLF10 expression is downregulated in pancreatic cancer and kidney cancer. 17, 18 KLF4 can inhibit the growth, migration and infiltration of the liver cancer cell line MM189, while KLF6 can inhibit intestinal cancer growth and infiltration. 19 Finally, KLF8 expression can promote the proliferation, infiltration and epithelial-mesenchymal transition (EMT) of liver cancer cells. 20 In liver cancer cells, KLF9
binds to the promoter region of the P53 gene and upregulates P53 expression to promote cell apoptosis and inhibit tumor progression. 21 In HepG2 cells, the downregulation of KLF17 can promote EMT in cells and can enhance the ability of tumor cell invasion. 22 In recent years, the role of KLF2 in tumor occurrence and development has been more frequently reported. KLF2 is downregulated in gastric cancer, liver cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. [23] [24] [25] Multiple long-chain noncoding RNA (TUG1, ANRIL, XIST and ZFAS1) and miRNA (miR-9)
can regulate KLF2 expression [23] [24] [25] [26] [27] [28] . Although the function of KLF2
in liver cancer has not been directly investigated and reported, relevant studies have indicated that long-chain non-coding RNA such as TUG1 and ANRIL can promote the occurrence of liver cancer and development by apparent silencing of KLF2 expression. 27 in liver cancer occurrence and development, and the molecular mechanism by which it is regulated, which provides a new strategy for HCC therapy.
| MATERIAL S AND ME THODS

| HCC sample collection
Liver tumor samples from HCC patients were obtained from The Longgang Central Hospital of Shenzhen, Shenzhen, China. All samples collected were obtained from patients who were admitted to the hospital for liver cancer from 2010 to 2016. None of the patients received any form of treatment (including chemotherapy and radiotherapy) before surgery. The organization collected permission from the hospital's biomedical ethics committee and informed consent from patients. All patients provided signed, informed consent.
| Mice
Alb-Cre (016832), P53 fl/fl (008462) and LSL-Kras G12D (019104) mice all had a C57BL/6 background and were purchased from Nanjing Biomedical Research Institute of Nanjing University and were originally obtained from The Jackson Laboratory. All mice were maintained under specific pathogen-free conditions.
Genotyping was performed using the following primers: Alb-Cre:
forward, 5′-AGGTGTAGAGAAGGCACTCAGC-3′, reverse, 5′-CTA ATCGCCATCTTCCAGCAGG-3′; P53: forward, 5′-CACAAAAACAGG TTAAACCCAG-3′; reverse, 5′-AGCACATAGGAGGCAGAGAC-3′; and Kras: forward, 5′-CTAGCCACCATGGCTTGAGT-3′; reverse, 5′-TCC GAATTCAGTGACTACAGATG-3′.
| Cells and reagents
Cells were maintained at 37°C under 5% CO 2 . L02, Chang, 7404
and Huh-7 cell lines were purchased from the Chinese Academy 
| Histological analysis
Paraffin-embedded samples were prepared from the livers of the experimental mice and HCC patients. Hematoxylin-eosin (HE) and immunohistochemistry (IHC) were used to stain the liver sections.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were performed using the ApoAlert DNA Assay Kit (Clontech, Mountain View, CA, USA).
| Plasmids and shRNA
and Gli1 (NM_005269.3) were amplified from reverse-transcribed were pooled and the expressions of KLF2 were examined using western blot analysis.
The plasmid pLKO.1 was also used as the carrier to construct the shRNA. The two target sequences are as follows:
shKLF2 1#, 5′-AACCCGAGTCCGGCGGCACCG-3; and shKLF2 2#, 5′-GAAGCGCGGCCGCCGCTCTTG-3′. 
| Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis
| Cell migration
Each Boyden chamber was divided into upper and lower layers so that film with holes could be placed in the middle. Collagen The film was then rinsed with clean water, and then images were obtained under the microscope.
| Colony-formation assay
First, 1.25% low melting-point agar was placed in a 42°C water bath for more than 1 hour, and a lower-layer gel was prepared with 20% FBS, 40% 2 × DMEM and 40% 1.25% agar. This layer was mixed well and placed on a 24-well plate with 200 μL/well, coagulated and then placed into a 37°C incubator. After the cells were 70% confluent, they were digested, suspended and diluted to 2.5 × 10 4 cells/ mL. The upper-layer gel comprised the following: 25% FBS, 37.5%
and 37.5% 1% agar. This gel was mixed with cells at a ratio of 4:1 and was then rapidly added to the lower-layer gel at 200 μL/well. The mixture was maintained in a 37°C incubator for 2 weeks, after which images were obtained and the colony numbers were counted. Each cell type was plated in four parallel wells, and all experiments were performed three times.
| Intrahepatic metastasis model
In all, 1 × 10 5 cells were injected into each mouse. Male nude mice aged 5 weeks were selected and each group comprised nine mice.
After anesthesia, the dermal and muscular layers were cut along the abdominal midline to expose the liver. Cells were injected into the largest lobe of the liver, and then tweezers were used for extrusion and hemostasis. Then, the mouse's muscular and dermal layers were sutured. After the experiment, the mice were killed by cervical dislocation, and the lobes that were injected with cells and those that were not injected were fixed and embedded. After HE staining, tumor cell metastasis was determined. When the survival time was analyzed, the injection time was determined to be the starting point, and the duration until death for all mice in each group was the primary end-point, according to which the survival curve was plotted.
| Dual-luciferase reporter assay
7404 or Huh-7 cells were transfected with the Gli1 luciferase reporter, TK-renilla and the indicated plasmids by Polyethylenimine (Polysciences, Warrington, PA, USA) according to the manufacturer's instructions. After 24 hours, the cells were harvested, and the luciferase activity was measured using a dual-luciferase reporter assay system according to the manufacturer's instructions (Promega,
Madison, WI, USA).
| Immunostaining
7404 cells were mounted on coverslips, fixed, permeabilized and then stained with the indicated antibodies and Hoechst. Images were obtained using an Olympus IX81 microscope (Tokyo, Japan) or a Leica confocal microscope (Wetzlar, Germany). Fluorescence imaging analysis was performed in a blinded manner, and densitometry quantification or Pearson's correlation was determined by ImagePro 6.0 software.
| Expression and purification of recombinant proteins
Full-length human KLF2 was constructed as part of the pGEX4T- 
| GST pull-down
GST-KLF2 or GST proteins at equimolar concentrations were incubated with 7404 and Huh-7 cell lysates at 4°C for 2 hours in
NP-40 and 10 μg/mL bovine serum albumin, pH 7.5) followed by three washes. Samples were combined with sodium dodecylsulfate (SDS) loading buffer and were subjected to SDS polyacrylamide gel electrophoresis (PAGE) without boiling. 
| Immunoprecipitation analysis
| Statistical analysis
All sample sizes were sufficient to ensure proper statistical analysis. Data are represented as the means ± standard error of the mean of at least three experiments. Statistical analyses were performed using GraphPad Prism 6 software, version 6. Statistical significance was calculated using Student's two-tailed unpaired ttest. The log-rank (Mantel-Cox) test was used for survival comparisons (P > 0.05, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). showed that KLF2 expression in normal liver cells (L02 and Chang) was higher than in liver cancer cells (see Figure S1 ).
| RE SULTS
| KLF2 expression is reduced in HCC
In liver cancer, P53 deletion and the Kras ) ( Figure 1F ). These studies showed that KLF2 is downregulated in liver cancer. ) and in control tissues, and the quantification was performed F I G U R E 2 Krüppel-like factor 2 (KLF2) inhibits liver cancer cell growth, migration and colony-formation ability. A, MTT assay was used to study the effect of overexpressed KLF2 on liver cancer cell growth. B,C, Borden chamber experiment was used to study the effect of KLF2 overexpression on liver cancer cell migration (scale bar: 100 μm, representative images). D,E, Soft agar colony experiment was used to study the effect of KLF2 overexpression on the anchorage-independent growth of cancer cells. F, MTT assay was used to study the effect of downregulating KLF2 on liver cancer cell growth. (G,H) Borden chamber experiment was used to study the effect of KLF2 downregulation on liver cancer cell migration (scale bar: 100 μm, representative images). I,J, Soft agar colony experiment was used to study the effect of KLF2 overexpression on the anchorage-independent growth of cancer cells. *P < 0.05; **P < 0.01
| KLF2 inhibits liver cancer cell growth, migration and colony formation
and Huh-7. After 72 hours, we sorted the GFP-positive cells and performed a western blot to detect the expression of Flag-KLF2 (see Figure S2a) Experimental results showed that, on the 8th day, the OD value of the control cells was significantly higher than that of 7404 cells and Huh-7 cells that overexpressed KLF2 (Figure 2A) . 
E). Such results
showed that upregulated KLF2 could inhibit the colony-formation ability of liver cancer cells. Figure S2b) . We used an MTT assay to detect the effect of KLF2 downregulation on cell growth.
The experimental results showed that after KLF2 expression was downregulated, on days 6 and 8 of the experiment, the OD value of the experimental group was significantly higher than that of the control group, which indicated that interference of KLF2 expression promoted the growth of liver cancer cells ( Figure 2F ). Next, we performed a Boyden chamber assay to detect the effect of KLF2
downregulation on liver cancer cell migration. The results showed that after KLF2 expression was downregulated, the number of migrated cells was significantly higher than that of the control group 
| KLF2 inhibits the Hedgehog/Gli1 signaling pathways in liver cancer cells
In previous studies, we demonstrated the potential biological function of KLF2 in liver cancer occurrence by analyzing the expression of KLF2 in liver cancer tissue and detecting the effect of KLF2 expression on the growth, migration and metastasis of liver cancer cells. However, the mechanism of KLF2 in the regulation of liver cancer cell growth, migration and metastasis has not been clearly demonstrated. First, using a luciferase reporter system, we screened the Moreover, the expression of KLF2 was negatively correlated with the expression of Gli1 and Patch ( Figure 4E ). This demonstrated that KLF2 can actually inhibit liver cancer occurrence and development through inhibition of Hedgehog/Gli1 signaling pathway.
| KLF2 interacts with Gli1 in HCC cells
Previous studies showed that KLF2 inhibits the Hedgehog/Gli1 signaling pathway, but the detailed mechanism by which KLF2 suppresses the Hedgehog/Gli1 signaling pathway has not been clearly
shown. Considering the function of KLF2 as a transcription factor, we first investigated the interaction between KLF2 and the transcription machinery of the Hedgehog/Gli1 signaling pathway in the cell nucleus. Gli1 is one of the most important transcription factors in Hedgehog/Gli1 signaling. Thus, we first detected the interaction between KLF2 and Gli1. We purified the GST-KLF2 recombinant protein, which was incubated with 7404 or Huh-7 cells in lysis buffer overnight; GST protein served as the control ( Figure 5A ).
The results showed that the endogenously expressed Gli1 protein and Gli1 were co-localized ( Figure 5D ). As a transcription factor located in the cell nucleus, Gli1 can interact with multiple proteins.
We next determined that the C-terminal of Gli1 was responsible for its binding with KLF2 ( Figure 5E ). It has been reported that HDAC1
can interact with and deacetylate the C-terminal of Gli1, which results in Hedgehog/Gli1 signal pathway activation. 32 Finally, we investigated whether KLF2 could negatively regulate the interaction between HDAC1 and Gli1. As shown in Figure 5 (F), The activation of Hedgehog/Gli1 signal pathway by HDAC1 could be repressed by KLF2. In addition, in 7404 cells, overexpressed KLF2 inhibited the interaction between HDAC1 and Gli1 ( Figure 5G ). These studies showed that KLF2 may negatively regulate the Hedgehog/Gli1 signaling pathway by inhibiting the interaction between HDAC1
and Gli1.
| D ISCUSS I ON
Hepatocellular carcinoma is one of the most common malignant tumors in China. Therefore, studies on the molecular mechanism of HCC occurrence and development are of great significance for the diagnosis and treatment of this disease. In this study, we discovered that in the process of HCC occurrence, KLF2 expression was downregu- 33 Additionally, relevant studies have shown that through vascular endothelial growth factor upregulation, Gli1 can promote the infiltration and metastasis of skin squamous cell carcinoma. 34 We also found that Gli1 can promote the metastasis of brain tumor cells.
35
Such studies have shown that KLF2 may inhibit the migration capacity of liver cancer cells by inhibiting the expression of Gli1 target genes.
In angiogenesis, KLF2 can mediate the inhibition of endothelial cell migration, which results from ERK5 inactivation, by inhibiting PAK1
expression. 36 In tumorigenesis, KLF2 expression is downregulated in pancreatic ductal adenocarcinoma, as its overexpression inhibits the migration and metastasis of adenocarcinoma.
32
This study demonstrated the important role of the interaction between KLF2 and Gli1 in the regulation of Hedgehog signaling activation. Gli1 protein can be modified, such as by phosphorylation, acetylation and ubiquitination. The acetyltransferase P300/ CBP-associated factor can acetylate Gli1, which inhibits Gli1 transcriptional activity. 37, 38 The deacetylase HDAC1 promotes the deactivation of Gli1, which activates the Hedgehog/Gli1 signaling pathway. 39 In this study, we revealed that KLF2 expression can inhibit the interaction between HDAC1 and Gli1, which demonstrates that HDAC1 and KLF2 may competitively bind to Gli1. In normal cells, the interaction of KLF2/Gli1 is balanced with that of HDAC1/ Gli1. In tumor cells, changes in the expression of KLF2 and HDAC1 disrupt the balance between the interaction of KLF2/Gli1 and that of HDAC1/Gli1, and in this case, the Hedgehog/Gli1 signaling pathway is overactivated and tumors develop. Consistent with this hypothesis, some studies have reported on the upregulation of HDAC1
in liver cancer tissue, 40 while our study also showed that KLF2 expression is downregulated in liver cancer tissue. These study results
showed that the increased interaction between HDAC1 and Gli1 can activate the transcriptional activity of Gli1.
In conclusion, we observed that KLF2 expression in HCC tissue is downregulated and that KLF2 can inhibit the growth, migration and metastasis of liver cancer cells by inhibiting the Hedgehog/Gli1 signaling pathway. These findings propose KLF2 as a promising diagnostic marker for HCC occurrence, and the re-expression of KLF2
in liver cancer cells may also be considered a new strategy for HCC treatment. 
ACK N OWLED G M ENTS
CO N FLI C T S O F I NTE R E S T
Authors declare no conflict of interest for this article.
O RCI D
Tao Chen https://orcid.org/0000-0002-8433-2509
